Oncolytics Biotech Inc. Q3 2024 Earnings Call Transcript
| ONCY Stock | USD 0.54 0.02 3.85% |
Slightly above 55% of Oncolytics Biotech's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Oncolytics Biotech suggests that some traders are interested. Oncolytics Biotech's investing sentiment can be driven by a variety of factors including economic data, Oncolytics Biotech's earnings reports, geopolitical events, and overall market trends.
Oncolytics | Build AI portfolio with Oncolytics Stock |
Operator Good afternoon and welcome to Oncolytics Biotech
Read at insidermonkey.com
 |
Oncolytics Biotech Fundamental Analysis
We analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Oncolytics Biotech is currently under evaluation in target price category among its peers.
Oncolytics Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oncolytics Biotech stock to make a market-neutral strategy. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics with similar companies.
Peers
Oncolytics Biotech Related Equities
| MCRB | Seres Therapeutics | 11.61 | ||||
| MIST | Milestone Pharmaceuticals | 8.11 | ||||
| PPCB | Propanc Biopharma | 4.96 | ||||
| DMAC | DiaMedica Therapeutics | 4.64 | ||||
| SCPH | Scpharmaceuticals | 1.64 | ||||
| TERN | Terns Pharmaceuticals | 0.66 | ||||
| XFOR | X4 Pharmaceuticals | 0.89 | ||||
| CVAC | CureVac NV | 3.34 | ||||
| KRYS | Krystal Biotech | 3.64 | ||||
| DAWN | Day One | 4.59 | ||||
| IKT | Inhibikase Therapeutics | 4.76 | ||||
| VIR | Vir Biotechnology | 5.91 | ||||
| HOOK | Hookipa Pharma | 11.56 |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.